Graphite Bio
South San Francisco
CA
United States
55 articles about Graphite Bio
-
Graphite Bio Presents Preclinical Data Supporting GPH101 in Sickle Cell Disease at 49th Annual Sickle Cell Disease Association of America National Convention
10/12/2021
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced today the presentation of preclinical data for GPH101, an investigational therapy designed to directly correct the genetic mutation responsible for sickle cell disease (SCD).
-
Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
10/5/2021
Graphite Bio Announces Upcoming Presentation at 49th Annual Sickle Cell Disease Association of America National Convention
-
Graphite Bio Announces Participation in Upcoming September Investor Conferences
8/30/2021
Graphite Bio, Inc. today announced that members of the management team will participate in virtual fireside chats at the following investor conferences: Morgan Stanley 19th Annual Global Healthcare Conference on Monday, Sept. 13, 2021
-
Graphite Bio Reports Recent Business Progress and Second Quarter 2021 Financial Results
8/12/2021
Graphite Bio, Inc., a clinical-stage, next-generation gene editing company harnessing high-efficiency precision gene correction to treat or cure serious diseases, reported recent business progress and second quarter 2021 financial results.
-
Graphite Bio Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/30/2021
Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share on June 29, 2021.
-
Multiple pharma company stocks make their first appearance on the Nasdaq this morning to advance the next-generation therapeutics. BioSpace takes a look at some of these IPOs.
-
Graphite Bio Announces Pricing of Upsized Initial Public Offering
6/24/2021
Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the pricing of its upsized initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share
-
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
-
Graphite Bio Appoints Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to Board of Directors
5/4/2021
Graphite Bio, Inc. , a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the appointments of Dr. Kristen Hege, Smital Shah and Dr. Jo Viney to its board of directors.
-
Graphite Bio Appoints Jane Grogan, Ph.D., as Chief Scientific Officer
4/27/2021
Dr. Grogan Brings More Than 20 Years of Industry Experience Building Research Teams and Executing Drug Development Strategies Across Therapeutic Areas and Modalities
-
Money on the Move: March 10-16
3/17/2021
Life sciences money is seemingly growing on trees this year. Here's who picked a good harvest this week. -
Graphite Bio Secures $150 Million Series B Financing to Advance Pipeline of Next-Generation Gene Editing Therapies
3/15/2021
Total of $195 million raised to date to support expansion and clinical advancement of Graphite Bio pipeline of targeted gene integration therapies with curative potential The financing, led by RA Capital Management and Rock Springs Capital, included participation by other prominent new and existing investors
-
Several biotech companies have announced closings of million-dollar financing rounds Monday, with Cambridge, Mass.-based cell and gene therapy company ElevateBio leading the pack. ElevateBio announced it raised $525 million in a Series C financing round, which the company says should help expand ...
-
Jasper Therapeutics and Graphite Bio Announce Collaboration to Evaluate JSP191 as Conditioning Regimen for Novel Gene Replacement Therapy in Patients with XSCID
1/13/2021
Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, and Graphite Bio, Inc., a next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced a research and clinical collaboration agreement to evaluate JSP191, Jasper’s first-in-class anti-CD117 monoc
-
The company was backed by Versant Ventures, which supported the launch of CRISPR Therapeutics.